Please dial in at one of the following numbers a few minutes before the start of the conference call:
- From Sweden: +46 (0) 8 505 564 74
- From the US: +1 855 753 22 30
- From the UK: +44 (0) 2033 645 374
The webcast can be accessed from the following web address:
http://www.media-server.com/m/p/sepj3xpf
Host: Bruno Lucidi, CEO.
The webcast from the Capital Markets Day can be accessed from the following web address:
http://financialhearings.nu/141021/karolinskadevelopment/
For further information, please contact:
Bruno Lucidi, CEO, Karolinska Development AB
Phone: +46 (0)72 245 9892, e-mail: bruno.lucidi@karolinskadevelopment.com
TO THE EDITORS
About Karolinska Development AB
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into differentiated products that can be partnered. The business model is to: SELECT the most commercially attractive medical innovations that can potentially satisfy unmet medical needs; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading universities, delivers a continuous flow of innovations. Today, the portfolio consists of 33 projects, of which 16 are in clinical development. For more information, please visit www.karolinskadevelopment.com.
Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.
